首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Quantitation of hepcidin in serum using ultra‐high‐pressure liquid chromatography and a linear ion trap mass spectrometer
Authors:Sukhvinder S Bansal  Vincenzo Abbate  Adrian Bomford  John M Halket  Iain C Macdougall  Swee Lay Thein  Robert C Hider
Institution:1. Pharmaceutical Sciences Division, King's College London, 150 Stamford Street, Waterloo, London SE1 9NH, UK;2. Nutritional Sciences Division, King's College London, 150 Stamford Street, Waterloo, London SE1 9NH, UK;3. Institute of Liver Studies, King's College London, King's College Hospital, London SE5 9RS, UK;4. Department of Renal Medicine, King's College Hospital, London SE5 9RS, UK;5. Division of Gene and Cell Based Therapy, King's College London, James Black Centre, London SE5 9NU, UK and Department of Haematological Medicine, King's College London, Kings College Hospital, London SE5 9RS, UK
Abstract:Hepcidin is a peptide hormone that functions as a key regulator of mammalian iron metabolism. Biological levels are increased in end‐stage renal disease and during inflammation but suppressed in hemochromatosis. Thus hepcidin levels have diagnostic importance. This study describes the development of an analytical method for the quantitative determination of the concentration of hepcidin in clinical samples. The fragmentation of hepcidin was investigated using triple quadrupole and linear ion trap mass spectrometers. A standard quantity of a stable isotopically labelled hepcidin internal standard was added to serum samples. Extraction was performed by protein precipitation and weak cation‐exchange magnetic nanoparticles. Chromatography was carried out on sub 2 µm particle stationary phase, using ultra‐high‐pressure liquid chromatography and a linear ion trap for quantitation. The lower limit of quantitation was 0.4 nmol/L with less than 20% accuracy and precision. The mean hepcidin concentration in sera for controls was 4.6 ± 2.7 nmol/L, in patients with sickle cell disease, 7.0 ± 8.9 nmol/L; in patients with end‐stage renal disease, 30.5 ± 15.7 nmol/L; and patients with penetrant hereditary hemochromatosis, 1.4 ± 0.8 nmol/L. Copyright © 2010 John Wiley & Sons, Ltd.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号